Histamine-2-receptor antagonists and gastric cancer risk

C. La Vecchia, E. Negri, B. D'Avanzo, C. La Vecchia, S. Franceschi

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

The relation between use of histamine-2-receptor (H2-receptor) antagonists and gastric cancer risk was investigated in a case-control study in northern Italy. 563 patients with newly diagnosed, histologically confirmed gastric cancer were compared with 1501 controls who did not have neoplastic or gastrointestinal disorders. 36 (6·3%) cases and 59 (3·3%) controls had used H2-receptor antagonists (cimetidine or ranitidine). The relative risk (RR) for ever-use was 1·8 (95% confidence intervals [Cl] 1·2, 2·7). The increased risk was restricted to patients who had started treatment with H2-receptor antagonists within 5 years of the diagnosis of stomach cancer (RR 3·1; 95% Cl 1·8, 5·3). For first use of H2-receptor antagonists 5-9 years previously the RR was 1·5 (95% Cl 0·7, 3·3), and for first use 10 or more years previously RR was 0·2 (95% Cl 0·03, 0·8). Although the incidence of gastric cancer was raised for the first few years after the start of treatment with H2-receptor antagonists, this may reflect misdiagnosis of some early gastric cancers. The findings are against long-term persistence of an excess risk of gastric cancer in association with use of H2-receptor antagonists.

Original languageEnglish
Pages (from-to)355-357
Number of pages3
JournalLancet
Volume336
Issue number8711
DOIs
Publication statusPublished - Aug 11 1990

Fingerprint

Histamine Receptors
Stomach Neoplasms
Ranitidine
Cimetidine
Diagnostic Errors
Italy
Case-Control Studies
Confidence Intervals
Incidence
Therapeutics

ASJC Scopus subject areas

  • Medicine(all)

Cite this

La Vecchia, C., Negri, E., D'Avanzo, B., La Vecchia, C., & Franceschi, S. (1990). Histamine-2-receptor antagonists and gastric cancer risk. Lancet, 336(8711), 355-357. https://doi.org/10.1016/0140-6736(90)91888-H

Histamine-2-receptor antagonists and gastric cancer risk. / La Vecchia, C.; Negri, E.; D'Avanzo, B.; La Vecchia, C.; Franceschi, S.

In: Lancet, Vol. 336, No. 8711, 11.08.1990, p. 355-357.

Research output: Contribution to journalArticle

La Vecchia, C, Negri, E, D'Avanzo, B, La Vecchia, C & Franceschi, S 1990, 'Histamine-2-receptor antagonists and gastric cancer risk', Lancet, vol. 336, no. 8711, pp. 355-357. https://doi.org/10.1016/0140-6736(90)91888-H
La Vecchia C, Negri E, D'Avanzo B, La Vecchia C, Franceschi S. Histamine-2-receptor antagonists and gastric cancer risk. Lancet. 1990 Aug 11;336(8711):355-357. https://doi.org/10.1016/0140-6736(90)91888-H
La Vecchia, C. ; Negri, E. ; D'Avanzo, B. ; La Vecchia, C. ; Franceschi, S. / Histamine-2-receptor antagonists and gastric cancer risk. In: Lancet. 1990 ; Vol. 336, No. 8711. pp. 355-357.
@article{1b7ee6e29a9a4e25879d1933606f7b24,
title = "Histamine-2-receptor antagonists and gastric cancer risk",
abstract = "The relation between use of histamine-2-receptor (H2-receptor) antagonists and gastric cancer risk was investigated in a case-control study in northern Italy. 563 patients with newly diagnosed, histologically confirmed gastric cancer were compared with 1501 controls who did not have neoplastic or gastrointestinal disorders. 36 (6·3{\%}) cases and 59 (3·3{\%}) controls had used H2-receptor antagonists (cimetidine or ranitidine). The relative risk (RR) for ever-use was 1·8 (95{\%} confidence intervals [Cl] 1·2, 2·7). The increased risk was restricted to patients who had started treatment with H2-receptor antagonists within 5 years of the diagnosis of stomach cancer (RR 3·1; 95{\%} Cl 1·8, 5·3). For first use of H2-receptor antagonists 5-9 years previously the RR was 1·5 (95{\%} Cl 0·7, 3·3), and for first use 10 or more years previously RR was 0·2 (95{\%} Cl 0·03, 0·8). Although the incidence of gastric cancer was raised for the first few years after the start of treatment with H2-receptor antagonists, this may reflect misdiagnosis of some early gastric cancers. The findings are against long-term persistence of an excess risk of gastric cancer in association with use of H2-receptor antagonists.",
author = "{La Vecchia}, C. and E. Negri and B. D'Avanzo and {La Vecchia}, C. and S. Franceschi",
year = "1990",
month = "8",
day = "11",
doi = "10.1016/0140-6736(90)91888-H",
language = "English",
volume = "336",
pages = "355--357",
journal = "The Lancet",
issn = "0140-6736",
publisher = "Lancet Publishing Group",
number = "8711",

}

TY - JOUR

T1 - Histamine-2-receptor antagonists and gastric cancer risk

AU - La Vecchia, C.

AU - Negri, E.

AU - D'Avanzo, B.

AU - La Vecchia, C.

AU - Franceschi, S.

PY - 1990/8/11

Y1 - 1990/8/11

N2 - The relation between use of histamine-2-receptor (H2-receptor) antagonists and gastric cancer risk was investigated in a case-control study in northern Italy. 563 patients with newly diagnosed, histologically confirmed gastric cancer were compared with 1501 controls who did not have neoplastic or gastrointestinal disorders. 36 (6·3%) cases and 59 (3·3%) controls had used H2-receptor antagonists (cimetidine or ranitidine). The relative risk (RR) for ever-use was 1·8 (95% confidence intervals [Cl] 1·2, 2·7). The increased risk was restricted to patients who had started treatment with H2-receptor antagonists within 5 years of the diagnosis of stomach cancer (RR 3·1; 95% Cl 1·8, 5·3). For first use of H2-receptor antagonists 5-9 years previously the RR was 1·5 (95% Cl 0·7, 3·3), and for first use 10 or more years previously RR was 0·2 (95% Cl 0·03, 0·8). Although the incidence of gastric cancer was raised for the first few years after the start of treatment with H2-receptor antagonists, this may reflect misdiagnosis of some early gastric cancers. The findings are against long-term persistence of an excess risk of gastric cancer in association with use of H2-receptor antagonists.

AB - The relation between use of histamine-2-receptor (H2-receptor) antagonists and gastric cancer risk was investigated in a case-control study in northern Italy. 563 patients with newly diagnosed, histologically confirmed gastric cancer were compared with 1501 controls who did not have neoplastic or gastrointestinal disorders. 36 (6·3%) cases and 59 (3·3%) controls had used H2-receptor antagonists (cimetidine or ranitidine). The relative risk (RR) for ever-use was 1·8 (95% confidence intervals [Cl] 1·2, 2·7). The increased risk was restricted to patients who had started treatment with H2-receptor antagonists within 5 years of the diagnosis of stomach cancer (RR 3·1; 95% Cl 1·8, 5·3). For first use of H2-receptor antagonists 5-9 years previously the RR was 1·5 (95% Cl 0·7, 3·3), and for first use 10 or more years previously RR was 0·2 (95% Cl 0·03, 0·8). Although the incidence of gastric cancer was raised for the first few years after the start of treatment with H2-receptor antagonists, this may reflect misdiagnosis of some early gastric cancers. The findings are against long-term persistence of an excess risk of gastric cancer in association with use of H2-receptor antagonists.

UR - http://www.scopus.com/inward/record.url?scp=0025085635&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025085635&partnerID=8YFLogxK

U2 - 10.1016/0140-6736(90)91888-H

DO - 10.1016/0140-6736(90)91888-H

M3 - Article

C2 - 1975342

AN - SCOPUS:0025085635

VL - 336

SP - 355

EP - 357

JO - The Lancet

JF - The Lancet

SN - 0140-6736

IS - 8711

ER -